CN120082603A - 针对突变的ras的hla ii类限制性t细胞受体 - Google Patents

针对突变的ras的hla ii类限制性t细胞受体 Download PDF

Info

Publication number
CN120082603A
CN120082603A CN202510245856.3A CN202510245856A CN120082603A CN 120082603 A CN120082603 A CN 120082603A CN 202510245856 A CN202510245856 A CN 202510245856A CN 120082603 A CN120082603 A CN 120082603A
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
tcr
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202510245856.3A
Other languages
English (en)
Chinese (zh)
Inventor
拉米·约瑟夫
盖尔·卡弗里
保罗·F·罗宾斯
史蒂文·A·罗森伯格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of CN120082603A publication Critical patent/CN120082603A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4253—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • G01N33/57575—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
CN202510245856.3A 2017-09-20 2018-09-19 针对突变的ras的hla ii类限制性t细胞受体 Pending CN120082603A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762560930P 2017-09-20 2017-09-20
US62/560,930 2017-09-20
PCT/US2018/051641 WO2019060349A1 (en) 2017-09-20 2018-09-19 CLASS II HLA RESTRICTED T LYMPHOCYTE RECEPTORS AGAINST KRAS MUTATED
CN201880060535.4A CN111201237B (zh) 2017-09-20 2018-09-19 针对突变的ras的hlaii类限制性t细胞受体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880060535.4A Division CN111201237B (zh) 2017-09-20 2018-09-19 针对突变的ras的hlaii类限制性t细胞受体

Publications (1)

Publication Number Publication Date
CN120082603A true CN120082603A (zh) 2025-06-03

Family

ID=63963389

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202510245856.3A Pending CN120082603A (zh) 2017-09-20 2018-09-19 针对突变的ras的hla ii类限制性t细胞受体
CN201880060535.4A Active CN111201237B (zh) 2017-09-20 2018-09-19 针对突变的ras的hlaii类限制性t细胞受体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201880060535.4A Active CN111201237B (zh) 2017-09-20 2018-09-19 针对突变的ras的hlaii类限制性t细胞受体

Country Status (17)

Country Link
US (3) US11306132B2 (enExample)
EP (1) EP3684799A1 (enExample)
JP (1) JP7256794B2 (enExample)
KR (2) KR20250037592A (enExample)
CN (2) CN120082603A (enExample)
AR (1) AR112902A1 (enExample)
AU (2) AU2018335274B2 (enExample)
BR (1) BR112020005469A2 (enExample)
CA (1) CA3076339A1 (enExample)
CR (1) CR20240019A (enExample)
EA (1) EA202090652A1 (enExample)
IL (1) IL273254B2 (enExample)
MA (1) MA50180A (enExample)
MX (2) MX2020003117A (enExample)
SG (1) SG11202002425PA (enExample)
TW (1) TWI825029B (enExample)
WO (1) WO2019060349A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
WO2020154617A1 (en) * 2019-01-25 2020-07-30 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting mutant ras
KR20220052941A (ko) * 2019-07-30 2022-04-28 유니버시티 헬스 네트워크 T 세포 수용체 동정 방법
CN112759641B (zh) * 2019-11-01 2023-01-20 香雪生命科学技术（广东）有限公司 一种识别Kras G12V的高亲和力TCR
BR112022011795A2 (pt) 2019-12-20 2022-08-30 Instil Bio Uk Ltd Métodos para preparar e isolar uma população terapêutica de linfócitos e para tratar câncer em um indivíduo, população terapêutica de linfócitos, bolsa criopreservada, recipiente flexível, e, sistema para extração de linfócitos
EP4103598A1 (en) * 2020-02-14 2022-12-21 The United States of America, as represented by the Secretary, Department of Health and Human Services Hla class i-restricted t cell receptors against ras with g12v mutation
JP2023516137A (ja) * 2020-02-19 2023-04-18 エイリン・セラピューティクス Ｒａｓタンパク質を標的化する分子
JP7742354B2 (ja) * 2020-02-26 2025-09-19 アメリカ合衆国 Ｇ１２ｖ変異を有するｒａｓに対するｈｌａクラスｉｉ拘束性ｔ細胞受容体
US20230312672A1 (en) * 2020-06-24 2023-10-05 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Hla class i-restricted t cell receptors against cd20
JP2023534241A (ja) * 2020-07-13 2023-08-08 アメリカ合衆国 Ｇ１２ｄ変異を有するｒａｓに対するｈｌａクラスｉｉ拘束性ｄｒｂ ｔ細胞受容体
AU2021309958A1 (en) * 2020-07-16 2023-02-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HLA class II-restricted DRB T cell receptors against RAS with G12V mutation
CN112300269B (zh) * 2020-09-29 2022-12-09 中国科学院微生物研究所 Kras突变特异性t细胞受体筛选及抗肿瘤用途
WO2022072760A1 (en) * 2020-10-02 2022-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class ii-restricted dq t cell receptors against ras with g13d mutation
CA3202725A1 (en) * 2020-11-24 2022-06-02 Shanghai GenBase Biotechnology Co., Ltd. Ras mutant epitope peptide and t cell receptor recognizing ras mutant
IL305393A (en) 2021-02-25 2023-10-01 Alaunos Therapeutics Inc Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
WO2023150562A1 (en) 2022-02-01 2023-08-10 Alaunos Therapeutics, Inc. Methods for activation and expansion of t cells
CN114835800B (zh) * 2022-05-27 2023-10-13 重庆医科大学 Tcr或其抗原结合片段及其应用
CN117264043B (zh) * 2022-06-14 2024-05-10 上海镔铁生物科技有限责任公司 靶向kras g12v突变多肽的t细胞受体及其用途
WO2024072954A1 (en) * 2022-09-29 2024-04-04 Jerome Canady Research Institute for Advanced Biological and Technological Sciences Cold atmopsheric plasma treated pan-cancer epitope peptide within the collagen type vi a-3 (col6a3) protein as cancer vaccine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004021995A2 (en) 2002-09-06 2004-03-18 The Government Of The United States Of America, Represented By The Secretary, Departement Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
GB0328363D0 (en) * 2003-12-06 2004-01-14 Imp College Innovations Ltd Therapeutically useful molecules
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
WO2012129201A1 (en) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
AU2014407539B2 (en) * 2014-10-02 2020-10-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating T cell receptors having antigenic specificity for a cancer-specific mutation
CN118994363A (zh) * 2014-11-26 2024-11-22 美国卫生和人力服务部 抗突变的kras的t细胞受体
EP3325447A1 (en) * 2015-07-22 2018-05-30 Araxes Pharma LLC Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins
MX2018003062A (es) * 2015-09-15 2018-09-11 Us Health Receptores de celula t que reconocen kras mutante restringido en hla-cw8.
CN109790211B (zh) 2016-08-02 2024-03-26 美国卫生和人力服务部 抗kras-g12d t细胞受体

Also Published As

Publication number Publication date
AR112902A1 (es) 2019-12-26
JP2020534828A (ja) 2020-12-03
MA50180A (fr) 2021-05-26
US12304940B2 (en) 2025-05-20
AU2025202532A1 (en) 2025-05-01
IL273254B1 (en) 2024-05-01
US20250250318A1 (en) 2025-08-07
KR20250037592A (ko) 2025-03-17
AU2018335274A1 (en) 2020-04-09
AU2025202532A9 (en) 2025-09-04
MX2020003117A (es) 2020-08-20
CR20240019A (es) 2024-02-15
KR20200051804A (ko) 2020-05-13
EA202090652A1 (ru) 2020-08-21
TW201920251A (zh) 2019-06-01
US20220204584A1 (en) 2022-06-30
SG11202002425PA (en) 2020-04-29
TWI825029B (zh) 2023-12-11
JP7256794B2 (ja) 2023-04-12
US11306132B2 (en) 2022-04-19
CN111201237A (zh) 2020-05-26
CA3076339A1 (en) 2019-03-28
KR102777370B1 (ko) 2025-03-10
EP3684799A1 (en) 2020-07-29
AU2018335274B2 (en) 2025-02-13
CN111201237B (zh) 2025-03-25
WO2019060349A1 (en) 2019-03-28
IL273254B2 (en) 2024-09-01
IL273254A (en) 2020-04-30
US20190085046A1 (en) 2019-03-21
BR112020005469A2 (pt) 2020-09-29
MX2024004610A (es) 2024-04-30

Similar Documents

Publication Publication Date Title
US12304940B2 (en) HLA class II-restricted t cell receptors against mutated RAS
CN111836638B (zh) 针对突变的ras的hla i类限制性t细胞受体
CN113412277B (zh) 针对含有g12r突变的ras的hla第ii类限制性t细胞受体
EP4103598A1 (en) Hla class i-restricted t cell receptors against ras with g12v mutation
US20230159614A1 (en) Hla class ii-restricted t cell receptors against ras with g12v mutation
CN116322734A (zh) 针对具有g12d突变的ras的hla ii类限制性drb t细胞受体
EP4182029B1 (en) HLA-restricted class II DRB T lymphocyte receptors directed against RAS, including a G12V mutation
US20260008832A1 (en) Hla class ii-restricted t cell receptors against ras with g12r mutation
HK40060095A (en) Hla class ii-restricted t cell receptors against ras with g12r mutation
EA045621B1 (ru) T-клеточные рецепторы, рестриктированные по антигену лейкоцитов человека класса ii, против мутантного ras

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination